Real-world population pharmacokinetics of tezacaftor-ivacaftor in children with cystic fibrosis: The SYM-CF study. [PDF]
Br J Clin PharmacolAims: The clinical effectiveness of tezacaftor-ivacaftor in children with cystic fibrosis (cwCF) varies; some patients respond while others do not or have adverse effects.
Vonk SEM +7 more
europepmc +4 more sources
Cutaneous Adverse Effects of Elexacaftor-Tezacaftor-Ivacaftor: A Single Center Cohort Study on Acne Severity in Adults With Cystic Fibrosis. [PDF]
J Cosmet DermatolJournal of Cosmetic Dermatology, Volume 24, Issue 11, November 2025.
Smith AD +5 more
europepmc +4 more sources
Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor [PDF]
Pulmonary Therapy, 2020 Introduction The triple-combination (TC) cystic fibrosis transmembrane conductance regulator (CFTR) modulator regimen elexacaftor, tezacaftor, and ivacaftor was shown to be safe and efficacious in phase 3 trials of people with cystic fibrosis (pwCF) ≥ 12
Alice Tsai +6 more
doaj +2 more sources
Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor [PDF]
Frontiers in Pharmacology, 2023 Triple combination therapy with the CFTR modulators elexacaftor (ELX), tezacaftor (TEZ) and ivacaftor (IVA) has been qualified as a game changer in cystic fibrosis (CF).
Burkhard Tümmler, Burkhard Tümmler
doaj +3 more sources
Comparative efficacy and safety of CFTR modulators for people with cystic fibrosis with phe508del mutation: a systematic review and bayesian network meta-analysisResearch in context [PDF]
EClinicalMedicineSummary: Background: The development of cystic fibrosis transmembrane conductance regulator (CFTR) modulators (correctors and potentiators) emerged as a promising approach, aiming to restore CFTR protein function. A lack of head-to-head trials comparing
Mohammed Safeer V S +7 more
doaj +2 more sources
People with cystic fibrosis with high sputum neutrophil elastase on elexacaftor-tezacaftor-ivacaftor exhibit worse pulmonary function and pro-inflammatory airway milieu [PDF]
Scientific ReportsCystic fibrosis (CF) is a genetic condition affecting over 100,000 individuals worldwide. Lung disease is the main cause of mortality in CF, with chronic neutrophilic inflammation as a hallmark.
Alexandre Cammarata-Mouchtouris +9 more
doaj +2 more sources
Cutaneous and Ocular Rosacea Associated with Elexacaftor, Tezacaftor and Ivacaftor, A Treatment for Cystic Fibrosis: A Case Report. [PDF]
J Pediatr Clin PractPiednoir A +4 more
europepmc +2 more sources
Health Technology AssessmentBackground Cystic fibrosis is a life-limiting genetic condition that affects over 9000 people in England. Cystic fibrosis is usually diagnosed through newborn screening and causes symptoms throughout the body, including the lungs and digestive system ...
Steven J Edwards +7 more
doaj +2 more sources
Comparison of Stool Microbiome in Children with Cystic Fibrosis Treated with and Without Elexacaftor–Tezacaftor–Ivacaftor—A Pilot Study † [PDF]
Int J Mol SciSankararaman S +9 more
europepmc +3 more sources
Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis [PDF]
New England Journal of Medicine, 2017 Felix C C Ringshausen +2 more
exaly +2 more sources